Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Current variability in methods for tumor mutational burden (TMB) estimation and reporting demonstrates the urgent need for a homogeneous TMB assessment approach. Here, we compared TMB distributions in different cancer types using two customized targeted panels commonly used in clinical practice. Materials and Methods TMB spectra of 295- and 1021-gene panels in multiple cancer types were compared using targeted next-generation sequencing (NGS). The TMB distributions across a diverse cohort of 2,332 cancer cases were then investigated for their associations with clinical features. Treatment response data were collected for 222 patients who received immune-checkpoint inhibitors (ICIs) and their homologous recombination DNA damage repair (HR-DDR) and programmed death-ligand 1 (PD-L1) expression were additionally assessed and compared with the TMB and response rate. Results The median TMB between gene panels was similar despite a wide range in TMB values. The highest TMB was eight and 10 in patients with squamous cell carcinoma and esophageal carcinoma according to the classification of histopathology and cancer types, respectively. Twenty-three out of 103 patients (22.3%) were HR-DDR–positive and could benefit from ICI therapy; out of those 23 patients, seven patients had high TMB (p=0.004). Additionally, PD-L1 expression was not associated with TMB or treatment response among patients receiving ICIs. Conclusion Targeted NGS assays demonstrated the ability to evaluate TMB in pan-cancer samples as a tool to predict response to ICIs. In addition, TMB integrated with HR-DDR–positive status could be a significant biomarker for predicting ICI response in patients.
Abstract
Purpose Current variability in methods for tumor mutational burden (TMB) estimation and reporting demonstrates the urgent need for a homogeneous TMB assessment approach. Here, we compared TMB distributions in different cancer types using two customized targeted panels commonly used in clinical practice. Materials and Methods TMB spectra of 295- and 1021-gene panels in multiple cancer types were compared using targeted next-generation sequencing (NGS). The TMB distributions across a diverse cohort of 2,332 cancer cases were then investigated for their associations with clinical features. Treatment response data were collected for 222 patients who received immune-checkpoint inhibitors (ICIs) and their homologous recombination DNA damage repair (HR-DDR) and programmed death-ligand 1 (PD-L1) expression were additionally assessed and compared with the TMB and response rate. Results The median TMB between gene panels was similar despite a wide range in TMB values. The highest TMB was eight and 10 in patients with squamous cell carcinoma and esophageal carcinoma according to the classification of histopathology and cancer types, respectively. Twenty-three out of 103 patients (22.3%) were HR-DDR–positive and could benefit from ICI therapy; out of those 23 patients, seven patients had high TMB (p=0.004). Additionally, PD-L1 expression was not associated with TMB or treatment response among patients receiving ICIs. Conclusion Targeted NGS assays demonstrated the ability to evaluate TMB in pan-cancer samples as a tool to predict response to ICIs. In addition, TMB integrated with HR-DDR–positive status could be a significant biomarker for predicting ICI response in patients.
참고문헌 (36)
- Jiang T, "Tumor neoantigens : from basic research to clinical applications", J Hematol Oncol, 12, pp.93~ (2019)
- Chen L, "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4", Cell, 71, pp.1093~1102 (1992)
- Leach DR, "Enhancement of antitumor immunity by CTLA-4 blockade", Science, 271, pp.1734~1736 (1996)
- Larsen TV, "PD-L1 and PD-L2expression correlated genes in non-small-cell lung cancer", Cancer Commun(Lond), 39, pp.30~ (2019)
- Hirano F, "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity", Cancer Res, 65, pp.1089~1096 (2005)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Motzer RJ, "Nivolumab versus everolimus in advanced renal-cell carcinoma", N Engl J Med, 373, pp.1803~1813 (2015)
- Bracarda S, "Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies", Semin Oncol, 42, pp.495~505 (2015)
- Brahmer JR, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, 366, pp.2455~2465 (2012)
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
- Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
- Folprecht G, "Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer", Cancer Commun(Lond), 39, pp.74~ (2019)
- Shekarian T, "Pattern recognition receptors : immune targets to enhance cancer immunotherapy", Ann Oncol, 28, pp.1756~1766 (2017)
- Li A, "Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer", Clin Cancer Res, 23, pp.4929~4937 (2017)
- Buchhalter I, "Size matters : Dissecting key parameters for panel-based tumor mutational burden analysis", Int J Cancer, 144, pp.848~858 (2019)
- Heeke AL, "Prevalence of homologous recombination-related gene mutations across multiple cancer types", JCO Precis Oncol, 2018, pp.PO.17.0028~ (2018)
- Rimm DL, "A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer", JAMA Oncol, 3, pp.1051~1058 (2017)
- Campesato LF, "Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice", Oncotarget, 6, pp.34221~34227 (2015)
- Ma F, "Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer", Int J Cancer, 146, pp.1359~1368 (2020)
- Wang Y, "Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer", EBioMedicine, 43, pp.261~269 (2019)
- Zhou Z, "Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma", Thorac Cancer, 10, pp.839~847 (2019)
- Zhang Y, "The correlations of tumor mutational burden among singleregion tissue, multi-region tissues and blood in non-small cell lung cancer", J Immunother Cancer, 7, pp.98~ (2019)
- Sun S, "Identification of germline mismatch repair gene mutations in lung cancer patients with paired tumor-normal next generation sequencing : a retrospective study", Front Oncol, 9, pp.550~ (2019)
- Singal G, "Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database", JAMA, 321, pp.1391~1399 (2019)
- Yao Y, "Competitive endogenous RNA network construction and comparison of lung squamous cell carcinoma in smokers and nonsmokers", Dis Markers, 2019, pp.5292787~ (2019)
- Wang K, "Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations", Ann Oncol, 28, pp.748~753 (2017)
- Chalmers ZR, "Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
- Salem ME, "Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate", low, 2018, pp.29(Suppl 8), VIII649~VIII669
- Pursell ZF, "Yeast DNA polymerase epsilon participates in leading-strand DNA replication", Science, 317, pp.127~130 (2007)
- Petitjean A, "Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype : lessons from recent developments in the IARC TP53 database", Hum Mutat, 28, pp.622~629 (2007)
- Yang S, "Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation", J Cancer, 9, pp.2930~2937 (2018)
- Telli ML, "Homologous Recombination Deficiency(HRD)score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer", Clin Cancer Res, 22, pp.3764~3773 (2016)
- Teo MY, "Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1", PD-L1 blockade in advanced urothelial cancers, 2018, pp.36, 1685~1694
- 김수정, "Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer", Cancer Research and Treatment, 51(3), pp.1231~1240 (2019), 대한암학회
- Rosenberg JE, "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy : a single-arm, multicentre, phase 2 trial", Lancet, 387, pp.1909~1920 (2016)
- Labriola MK, "Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma", J Immunother Cancer, 8, pp.e000319~ (2020)